HDACs家族在乳腺癌中的研究进展  

Research Progress of HDACs Family in Breast Cancer

作　　者：苑豪芳 刘震[2] 达梦婷 张瑾 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院,乳腺疾病诊疗中心,青海 西宁

出　　处：《临床医学进展》2023年第6期9937-9946,共10页Advances in Clinical Medicine

摘　　要：近年来,组蛋白去乙酰化酶(Histone Deacetylase;HDACs)家族在乳腺癌发病机制中的研究备受关注。HDACs家族是一个重要的表观遗传学调节因子,可以去除组蛋白的乙酰基化修饰,从而影响基因的转录和表达。研究发现,HDACs家族在乳腺癌细胞中的表达与肿瘤的恶性程度和预后密切相关。目前,针对HDACs家族的抑制剂已成为乳腺癌治疗的重要策略之一。总之,HDACs家族在乳腺癌的研究进展为开发新的治疗策略提供了重要的理论基础和临床应用前景。Recently, the role of the histone deacetylase (HDACs) family in the pathogenesis of breast cancer is attracting attention. They are a family of important epigenetic regulators that suppress histone acetylation modifications, thereby affecting transcription and expression of genes. The expression of the HDAC family in breast cancer cells is found to be strongly associated with the malignancy and tumor prognosis. An inhibitor that currently targets the HDAC family is one of the key strategies for breast cancer treatment. In conclusion, advances in research on the HDAC family in breast cancer provide an important theoretical basis for the development of new therapeutic strategies and the prospect of clinical applications.

关 键 词：HDACS 组蛋白去乙酰化酶 乳腺癌 HDACI HDAC抑制剂 

分 类 号：R73[医药卫生—肿瘤]